67423-44-3

Basic information

• Product Name: O-METHYL-L-TYROSINE HYDROCHLORIDE
• Synonyms: H-TYR(ME)-OH HCL;H-TYR(ME)-OH HYDROCHLORIDE;O-METHYL-L-TYROSINE HYDROCHLORIDE;P-METHOXY-L-PHENYLALANINE HYDROCHLORIDE;4-Methoxy-L-PhenylalanineHCl);H-p-Methoxy-Phe-OH.HCl(H-Tyr(Me)-OH.HCl;4-Methoxy-L-Phenylalanine hydrochloride;H-Phe(4-OMe)-OH.HCl
• CAS NO: 67423-44-3
• Molecular Formula: C₁₀H₁₃NO₃*ClH
• Molecular Weight: 231.68
• Mol File: 67423-44-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 379.1°C at 760 mmHg
• Flash Point: 183.1°C
• Appearance: /
• Vapor Pressure: 2.01E-06mmHg at 25°C
• Storage Temp.: -20°C
• CAS DataBase Reference: O-METHYL-L-TYROSINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: O-METHYL-L-TYROSINE HYDROCHLORIDE(67423-44-3)
• EPA Substance Registry System: O-METHYL-L-TYROSINE HYDROCHLORIDE(67423-44-3)

Safety Data

• Hazardous Substances Data: 67423-44-3(Hazardous Substances Data)

Usage

General Description

O-Methyl-L-tyrosine hydrochloride is a chemical compound that is used as a building block in the synthesis of various pharmaceuticals and biochemical research. It is a derivative of the amino acid tyrosine, with a methyl group attached to the oxygen atom of the phenolic hydroxyl group. This modification can alter the pharmacokinetic and pharmacodynamic properties of tyrosine-containing drugs, leading to potential improvements in their therapeutic effects. O-Methyl-L-tyrosine hydrochloride is commonly used in the production of dopamine receptor agonists and as a precursor for the synthesis of dopaminergic drugs. Additionally, it may also have potential applications in the treatment of certain neurological and psychiatric disorders.

InChI:InChI=1/C10H13NO3.ClH/c1-14-8-4-2-7(3-5-8)6-9(11)10(12)13;/h2-5,9H,6,11H2,1H3,(H,12,13);1H/t9-;/m0./s1

Upstream product

• 7479-01-8 O-methyl-tyrosine methyl ester; hydrochloride 
• 824-94-2 p-methoxybenzyl chloride 
• 81961-88-8 ethyl 2-acetylamino-2-cyano-3-(4-methoxyphenyl)propanoate 
• 53612-87-6 2-acetylamino-2-(4-methoxybenzyl)malonic acid diethyl ester 

Downstream Products

• 70529-50-9 methyl 2-acetylamino-3-(4-methoxyphenyl)propanoate 
• 1575605-55-8 allyl 2-acetylamino-3-(4-methoxyphenyl)propanoate 
• 1575603-62-1 butyl 2-acetylamino-3-(4-methoxyphenyl)propanoate 
• 17355-24-7 (S)-N-acetyl-3-(4-methoxyphenyl)alanine methyl ester 
• 17355-24-7 methyl (R)-2-acetamido-3-(4-methoxyphenyl)propanoate 
• 1575603-64-3 allyl 2-acetylamino-3-(4-methoxyphenyl)propanoate 
• 7479-01-8 O-methyl-tyrosine methyl ester; hydrochloride 
• 1575604-59-9 C₁₄H₂₁NO₃*ClH 
• 82611-59-4 2-(((benzyloxy)carbonyl)amino)-3-(4-methoxyphenyl)propanoic acid 
• 152357-03-4 (S)-2-((methoxycarbonyl)amino)-3-(4-methoxyphenyl)propanoic acid 
• 80361-99-5 6-(dimethylamino)-9-<3'-<amino>-5'-chloro-3',5'-dideoxy-β-D-ribofuranosyl>purine 
• 80362-00-1 5'-chloro-5'-deoxypuromycin 
• 181649-60-5 methyl (2S,3aS,7aS)-1-benzyl-6-oxo-octahydroindole-2-carboxylate 
• 856571-30-7 2-{2-[(1H-indole-2-carbonyl)amino]benzoylamino}-3-(4-methoxyphenyl)propionic acid ethyl ester 

Relevant articles and documents

BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS

The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R1, R2, R3, R4, R6, R7, R8 and R9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"

In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.